FMP
Sep 27, 2021 8:03 PM - Davit Kirakosyan(Last modified: Dec 19, 2023 5:49 PM)
Analysts at Oppenheimer increased their price target on Prothena Corporation plc (NASDAQ:PRTA) to $100 from $90, as they refresh their favorable outlook on the company due to the recent update of FDA's Surrogate Endpoint Table, which now includes a reduction in amyloid-ß plaque for mAbs in mild-AD patients as appropriate for accelerated approval.
The analysts see confirmation that the company should benefit from regulatory precedence plus BIIB's launch efforts, noting that BIIB's Aduhelm was approved based on this surrogate endpoint.
Oct 31, 2023 8:03 AM - Parth Sanghvi
Free cash flow to the firm (FCFF) and free cash flow to equity (FCFE) are two of the most important metrics used in financial modeling. Both metrics measure the amount of cash that is available to a company's shareholders and creditors, but there is a key difference between the two. FCFF measures...
Nov 25, 2023 6:39 AM - Parth Sanghvi
Choosing the Right Valuation Method: DCF vs. Comparable Companies Analysis Introduction: Valuation methods play a pivotal role in determining the fair value of a company, aiding investors in making informed investment decisions. Two commonly used methods, DCF Valuation and Comparable Companies A...
Dec 23, 2023 2:19 AM - Parth Sanghvi
Introduction: Discounted Cash Flow (DCF) analysis stands as a cornerstone in valuing investments, yet its efficacy is contingent upon various assumptions and methodologies. While a powerful tool, DCF analysis comes with inherent limitations and challenges that investors must acknowledge to make i...